Imaging · Contrast AgentRegulatory Approvalregulatorymid-term

FDA Acceptance of Iohexol Supplement Application by Amneal

Importance7/ 10

ActionMonitor

AutoResearch

Multi-agent research across ingested FDA, EMA, MHRA, PMDA, PubMed, ClinicalTrials.gov, company documents, and Humanexa signals.

Last run 7/1/2026, 12:30:27 PM

Assessment confidence: 62% · The main uncertainty is timing and magnitude of competitive and regulatory follow-through.

Executive Thesis

The FDA's acceptance of Amneal's supplemental application for Iohexol is a significant regulatory milestone that could strengthen their competitive position in the imaging market. This development warrants close monitoring as it may influence market dynamics and competitive strategies among existing players. Regulatory context from FDA (FDA AP — IOHEXOL (SUPPL)) supports the near-term read. Assessment grounded in 20 ranked evidence items (7 high-relevance).

Strategic Assessment

Portfolio teams should evaluate the implications of this acceptance on market share and competitive strategies in imaging agents. The strongest clinical anchor is A Phase I/II Study of AZD4512 Monotherapy or in Combination With Anticancer Agents in Participants With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma (ClinicalTrials.gov), sponsor/company relevance (astrazeneca). In Imaging · Contrast Agent, 7 regulatory and 2 competitive items passed relevance filtering for Amneal.

Competitive Pressure

The most relevant competitive pressure comes from FDA Accepts Supplemental Application for TRYNGOLZA Autoinjector (Humanexa Signals) — moderate corpus alignment. Secondary pressure from FDA Approves Supplemental Application for AJOVY (Fremanezumab). This acceptance may enhance Amneal's position in the contrast agent market, potentially impacting competitors.

Regulatory Outlook

Regulatory risk is concentrated around FDA AP — IOHEXOL (SUPPL) (FDA). Entity match (amneal). The acceptance of the supplemental application indicates a positive regulatory trajectory, but the final approval will be critical for market entry and compliance.

Key Risks

Elevated medium regulatory exposure for Amneal could delay market entry or constrain labeling if agency review intensifies.

Key Opportunities

If approved, Iohexol could capture additional market share in the contrast agent segment, impacting revenue streams for both Amneal and its competitors.
Lead sponsor: AstraZeneca. This is Phase I/II open-label, global multicenter study to evaluate the safety and efficacy of AZD4512 monotherapy or in combination with other anticancer agent(s), in participants with Relapsed/Refractory B-cell Non-Hodgkin Lymphoma (B-NHL).
Upside for Amneal may improve if Rarely reported cases of hepatotoxicity associated with turmeric- and curcuminoid-containing dietary supplements: a comprehensive review by USP. (PubMed) delivers favorable follow-through.
Portfolio teams should evaluate the implications of this acceptance on market share and competitive strategies in imaging agents.

What Would Change This Assessment

This becomes more urgent if Monitor for further updates on the review process and any subsequent approvals or market entries.
Timeline shift beyond mid term would change urgency.
A competitor label expansion or pivotal readout in the same sub-indication would increase competitive pressure.

Supporting Evidence

FDA AP — IOHEXOL (SUPPL)
FDAhigh relevance
Entity match (amneal)
FDA document
View source
FDA AP — METHYLPREDNISOLONE SODIUM SUCCINATE (SUPPL)
FDAhigh relevance
Entity match (amneal)
FDA document
View source
FDA AP — HYDROCODONE BITARTRATE AND ACETAMINOPHEN (SUPPL)
FDAhigh relevance
Entity match (amneal)
FDA document
View source
FDA AP — TRAMADOL HYDROCHLORIDE (SUPPL)
FDAhigh relevance
Entity match (amneal)
FDA document
View source
FDA AP — HYDROCODONE BITARTRATE AND ACETAMINOPHEN (SUPPL)
FDAhigh relevance
Entity match (amneal)
FDA document
View source
IND Application Reporting: IND Safety Reports
FDAmedium relevance
Moderate corpus alignment
FDA document
View source
Investigational New Drug (IND) Application
FDAmedium relevance
Moderate corpus alignment
FDA document
View source

A Phase I/II Study of AZD4512 Monotherapy or in Combination With Anticancer Agents in Participants With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma
ClinicalTrials.govhigh relevance
Sponsor/company relevance (AstraZeneca)
FDA document
View source
Contrast-enhanced CBCT With C-arm HyperSight Technology
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
A Clinical Trial to Evaluate agenT-797 Plus Standard of Care in Participants With Severe Pneumonia With Moderate to Severe Acute Hypoxemic Respiratory Failure
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Natural History Study of CADASIL
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source

FDA Accepts Supplemental Application for TRYNGOLZA Autoinjector
Humanexa Signalsmedium relevance
Moderate corpus alignment
FDA Approves Supplemental Application for AJOVY (Fremanezumab)
Humanexa Signalsmedium relevance
Moderate corpus alignment

A 3.6:1 myo-inositol to D-chiro-inositol ratio and antioxidant-based food supplement before IVF improves fertility in women with PCOS: a pilot observational retrospective cohort study.
PubMedhigh relevance
Mechanism alignment (IO )
FDA document
View source
Selected immunoendocrine and performance adaptations to upper-body plyometric training and β-alanine supplementation in male swimmers.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Rarely reported cases of hepatotoxicity associated with turmeric- and curcuminoid-containing dietary supplements: a comprehensive review by USP.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
First-in-human evaluation of [(18)F]-AlF-NOTA-neurotensin for NTSR1-targeted imaging of prostate cancer: a head-to-head comparison with [(68)Ga]Ga-PSMA-617.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Effects of carnosine supplementation on physical endurance: a placebo-controlled randomized clinical trial.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Two-week essential oil inhalation treatment modulates the cortisol awakening response and improves self-reported symptoms in stressed adults.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Contrasting dietary patterns remodel gut microbial function and generate multi-omic signatures associated with cardiometabolic markers.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source

Regunera

Precedents · guidance

Reg

Loading regulatory precedents…

View full regulatory analysis

Competitiva

Competitors · threats

Intel

Loading competitive findings…

View full competitive analysis

Why this matters

Affected entities

Amneal
Iohexol

Commercial impact

medium

If approved, Iohexol could capture additional market share in the contrast agent segment, impacting revenue streams for both Amneal and its competitors.

Regulatory impact

medium

The acceptance of the supplemental application indicates a positive regulatory trajectory, but the final approval will be critical for market entry and compliance.

What to watch

Monitor for further updates on the review process and any subsequent approvals or market entries.

Recommended action

Monitor

Track for follow-up milestones; no immediate action required.